Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) could be just weeks away from having the first approved therapy, after UCB's Kygevi was recommended by the EMA's human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results